Bibliography
- BEARD CJ, COLEMAN CN, KINSELLA TJ: Radiation sensitizers. In: Cancer: Principles & Practice of Oncology VT DeVita Jr, S Hellman, SA Rosenberg (Eds), J.B. Lippincott, Philadelphia, USA (1993):2701–2713.
- BROWN JM: 5R4223 (Tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer (1993) 67:1163–1170.
- MILLER RA, WOODBURN K, FAN Q, RENSCHLER ME SESSLER JL, KOUTCHER JA: In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int. Radiat. Oncol Biol. Phys. (1999) 45:981–989.
- XU S, ZAKIAN K, THALER H et al.: Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity. Int. J. Oncol Biol. Phys. (2001) 49(5):1381–1390.
- MEHTA MP, RODRIGUS P, TERHAARD CHJ et al.: Motexafin Gadolinium prolongs time to neurologic progression in lung cancer patients with brain metastases: results of a randomized Phase III trial. hit. J. Radiat. Oncol Biol. Phys. (2002) 54:92 (Abstract)
- MEHTA MP, RODRIGUS P, TERHAARD CHJ et al.: Survival and neurological outcomes in a randomized trial of motexafin Gadolineum and whole brain radiation therapy in brain metasteses. Clin. Oncol (Presented for review).
- TIMMERMAN B, CARDE P, KOPROWSKI C et al.: Phase IB/II trial of the radiation sensitizer gadolinium texaphyrin (Gd-Tex) for patients with brain metastases: Final results. Int. J. Radial-. °flea Biol. Phys. (1998) 42:198 (Abstract).
- CARDE P, TIMMERMAN R, MEHTA MP et al.: Multicenter Phase lb/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases.j Clin. Oncol (2001) 19:2074–2083.
- VIALA J, VANEL D, MEINGAN P, LARTIGAU E, CARDE P, RENSCHLER M: Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases. Radiology (1999) 212(3):755–759.
- SESSLER JL, MILLER RA: Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem. Pharmacol (2000) 59:733–739.
- MODY TD, FU L, SESSLERJL: Texaphyrins: synthesis and development of a novel class of therapeutic agents. In: Progress in Inorganic Chemistry KD Karlin (Ed.), John Wiley & Sons Inc, New York (2001):551–598.
- YOUNG SW, QING F, HARRIMAN A et al.: Gadolinium (III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc. Natl. Acad. Sci. USA (1996) 93:6610–6615.
- BERNHARDE EJ, MITCHELL JB, DEEN D, CARDELL M, ROSENTHAL DI, BROWN JM: Re-evaluating gadolinium texaphyrin as a radiosensitizing agent. Cancer Res. (2000) 60:86–91.
- MILLER RA, WOODBURN KW, FAN Q et al.: Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin. Clin. Cancer Res (2001) 7:3215–3221.
- MAGDA D, LEPP C, GERASIMCHUK N et al.: Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int. J. Radiat. Oncol Biol. Phys. (2001) 51(4):1025–1036.
- MAGDA D, GERASIMCHUK N, LECANE P, MILLER RA, BIAGLOW JE, SESSLER JL: Motexafin gadolineum reacts with ascorbate to produce reactive oxygen species. Chem. Commun. (2002)15:2730–2731.
- MEHTA MP, SHAPIRO WR, GLANTZ MJ et al.: Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. Oncol (2002) 20:3445–3453.
- FORD JM, ENDICOT T, ALDER JR et al.: A Phase I dose escalation trial of motexafin gadolineum as a radiation sensitizer in patients with newly diagnosed glioblastoma multiforme. bit. J. Radial-. Oncol Biol. Phys. (2001) 51:205.
- SUH J, METHA M, CHANG E et ak Phase II trial of motexafin gadolineum and cranial irradiation in newly diagnosed glioblastoma multiforme. Int. .1. Radiat. Oncol Biol. Phys. (2002) 54:246 (Abstract).